Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2019

01-01-2019 | Review Article

Awakening the “guardian of genome”: reactivation of mutant p53

Authors: Akshay Binayke, Sarthak Mishra, Prabhat Suman, Suman Das, Harish Chander

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2019

Login to get access

Abstract

The role of tumor suppressor protein p53 is undeniable in the suppression of cancer upon oncogenic stress. It induces diverse conditions such as cell-cycle arrest, cell death, and senescence to protect the cell from carcinogenesis. The rate of mutations in p53 gene nearly accounts for 50% of the human cancers. Upon mutations, the conformation gets altered and becomes non-native. Mutant p53 displays long half-life and accumulates in the nucleus and interacts with oncoproteins to promote carcinogenesis and these interactions present a formidable challenge for clinicians in therapy of the disease. Variety of approaches have been developed, through which native-like function of p53 can be restored, such as restoration of the native-like structure of p53, activating the p53 family members, etc. Modern scientific techniques have led to the discovery of a variety of molecules to reactivate mutant p53 and restore its transcriptional activity. These compounds include small molecules, various peptides, and phytochemicals. In this review article, we comprehensively discuss these molecules to reactivate mutant p53 to restore the normal function with a particular focus on molecular mechanisms.
Literature
1.
go back to reference Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724–737CrossRefPubMed Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724–737CrossRefPubMed
8.
go back to reference Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53CrossRefPubMed Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53CrossRefPubMed
10.
go back to reference Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23(5):634–646CrossRefPubMedPubMedCentral Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23(5):634–646CrossRefPubMedPubMedCentral
11.
go back to reference Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359–39367CrossRefPubMed Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359–39367CrossRefPubMed
23.
go back to reference Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG (1998) Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 8(5):369–378CrossRefPubMed Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG (1998) Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 8(5):369–378CrossRefPubMed
26.
go back to reference Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3(6):632–638CrossRefPubMed Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3(6):632–638CrossRefPubMed
31.
go back to reference Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507–2510CrossRefPubMed Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507–2510CrossRefPubMed
32.
go back to reference Wang W, Takimoto R, Rastinejad F, El-Deiry WS (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23(6):2171–2181CrossRefPubMedPubMedCentral Wang W, Takimoto R, Rastinejad F, El-Deiry WS (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23(6):2171–2181CrossRefPubMedPubMedCentral
36.
go back to reference Hainaut P, Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Can Res 53(19):4469–4473 Hainaut P, Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Can Res 53(19):4469–4473
42.
go back to reference Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer cell 15(5):376–388CrossRefPubMed Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer cell 15(5):376–388CrossRefPubMed
44.
go back to reference Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, Desai D, Amin S, Lightfoot S, Kopelovich L (2013) Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia (New York, NY) 15(9):1018–1027CrossRef Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, Desai D, Amin S, Lightfoot S, Kopelovich L (2013) Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia (New York, NY) 15(9):1018–1027CrossRef
46.
go back to reference Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman K, Paul C (2006) PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 132(2):230–236CrossRefPubMed Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman K, Paul C (2006) PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 132(2):230–236CrossRefPubMed
47.
go back to reference Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639. https://doi.org/10.1200/jco.2011.40.7783 CrossRefPubMed Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639. https://​doi.​org/​10.​1200/​jco.​2011.​40.​7783 CrossRefPubMed
58.
go back to reference Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR (2004) Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation”. J Mol Biol 336(1):187–196CrossRefPubMed Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR (2004) Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for “mutant conformation”. J Mol Biol 336(1):187–196CrossRefPubMed
59.
go back to reference Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B (2010) SCH529074, a small molecule activator of mutant p53, which binds p53 DNA Binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285(14):10198–10212. https://doi.org/10.1074/jbc.M109.083469 CrossRefPubMedPubMedCentral Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B (2010) SCH529074, a small molecule activator of mutant p53, which binds p53 DNA Binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285(14):10198–10212. https://​doi.​org/​10.​1074/​jbc.​M109.​083469 CrossRefPubMedPubMedCentral
60.
go back to reference Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D’Orazi G, Givol D, Amariglio N (2012) Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 131(4):E562–E568. https://doi.org/10.1002/ijc.26441 CrossRefPubMed Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, Rechavi G, D’Orazi G, Givol D, Amariglio N (2012) Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer 131(4):E562–E568. https://​doi.​org/​10.​1002/​ijc.​26441 CrossRefPubMed
64.
go back to reference Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR (2014) Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5(19):8879PubMedPubMedCentral Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR (2014) Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5(19):8879PubMedPubMedCentral
71.
go back to reference Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee J-H, Kong A-NT (2012) Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anti Cancer Agents Med Chem 12(10):1281–1305CrossRef Wang H, Khor TO, Shu L, Su Z, Fuentes F, Lee J-H, Kong A-NT (2012) Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anti Cancer Agents Med Chem 12(10):1281–1305CrossRef
74.
go back to reference Mori A, Lehmann S, Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M, Koeffler HP (2006) Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Can Res 66(6):3222CrossRef Mori A, Lehmann S, Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M, Koeffler HP (2006) Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Can Res 66(6):3222CrossRef
77.
go back to reference Clark R, Lee S-H (2016) Anticancer properties of capsaicin against human cancer. Anticancer Res 36(3):837–843PubMed Clark R, Lee S-H (2016) Anticancer properties of capsaicin against human cancer. Anticancer Res 36(3):837–843PubMed
80.
go back to reference Kuo P-L, Hsu Y-L, Chang C-H, Lin C-C (2005) The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223(2):293–301CrossRefPubMed Kuo P-L, Hsu Y-L, Chang C-H, Lin C-C (2005) The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223(2):293–301CrossRefPubMed
Metadata
Title
Awakening the “guardian of genome”: reactivation of mutant p53
Authors
Akshay Binayke
Sarthak Mishra
Prabhat Suman
Suman Das
Harish Chander
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3701-x

Other articles of this Issue 1/2019

Cancer Chemotherapy and Pharmacology 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine